Aberrant induction or expression of p53 in response to MDM2 inhibition predicts for aggressive disease. Display of time-to-first-therapy estimates for CLL cases with aberrant p53 induction (blue line) by immunoblotting as opposed to cases with p53 wild-type immunoblotting pattern (red line), using the Kaplan-Meier method.